Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery by Nardi, M et al.
© 2007 Nardi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2007:1(4) 527–533 527
ORIGINAL RESEARCH
Analgesic and anti-inﬂ  ammatory effectiveness 
of nepafenac 0.1% for cataract surgery
M Nardi1
C Lobo2
A Bereczki3
J Cano4
E Zagato5
S Potts6
G Sullins6
R Notivol7
for the International 
C-04-65 Study Group*
1Neuroscienze-Clinica Oculistica, 
Università degli Studi di Pisa, Pisa, 
Italy; 2AIBILI, Coimbra, Portugal; 
3Ophthalmology, Petz Aladár Hospital, 
Györ, Hungary; 4Oftalmología, 
Hospital Municipal, Badalona, Spain; 
5Alcon Italia, Milan, Italy; 6R&D, Alcon 
Research Ltd., Fort Worth, TX, USA; 
7Alcon Cusí, SA, Barcelona, Spain
*Members of the International 
C-04-65 Study Group are listed in the 
Acknowledgments
Correspondence: Ricardo Notivol
Alcon Cusí, S.A., Camil Fabra 58, 08320 
Barcelona, Spain
Tel +34 9349 77000 ext 3361
Fax +34 9349 77010
Email: ricardo.notivol@alconlabs.com
Background: To compare nepafenac 0.1% with placebo and ketorolac 0.5% for prevention 
and treatment of ocular pain and inﬂ  ammation after cataract surgery.
Methods: In a multi-center, randomized, placebo- and active-controlled, double-masked clinical 
trial, 227 patients with cataract were randomized to receive nepafenac 0.1%, ketorolac 0.5%, 
or placebo TID beginning 1 day pre-operatively and continuing for 21 days postoperatively. At 
each postoperative visit, cure rates and clinical success rates ( 5 aqueous cells and no ﬂ  are) 
were calculated, and investigators evaluated patients’ pain. On Day 7, patients judged ocular 
comfort after study drug instillation.
Results: Nepafenac 0.1% produced signiﬁ  cantly more cures compared to placebo at Day 14 
(76.3% vs 59.2%, p = 0.0241), more clinical successes from Day 7 onward (p   0.05), and more 
pain-free patients from Day 3 onward (p   0.05). Nepafenac 0.1% was superior to ketorolac 
0.5% in terms of clinical success at Day 14 (p = 0.0319) and in percentage of pain-free patients 
at Day 3 (p = 0.0366). Nepafenac 0.1% also demonstrated less discomfort upon instillation than 
ketorolac 0.5% (p = 0.0158).
Conclusion: The anti-inﬂ  ammatory efﬁ  cacy of nepafenac 0.1% is better than that of placebo; 
it is also more comfortable and at least equal to ketorolac 0.5% in the prevention and treatment 
of postoperative ocular pain and inﬂ  ammation.
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Introduction
Ocular inﬂ  ammation, which is common after cataract surgery, may cause patients to 
have postoperative pain and photophobia. Complications resulting from inﬂ  amma-
tion include increased intraocular pressure, posterior capsular opaciﬁ  cation, cystoid 
macular edema, and decreased visual acuity. Topical steroid therapy effectively treats 
inﬂ  ammation, but can increase intraocular pressure, inhibit wound healing, increase 
the likelihood of infection, or worsen an existing one (Heier et al 2000; Simone 
and Whitacre 2001). Cataract surgeons have therefore been interested in decreasing 
dependence on steroid use alone, seeking alternative or complementary treatments for 
postoperative inﬂ  ammation that are equally effective but have fewer complications 
than steroid therapy (O’Brien 2005). Combination therapy of steroids with nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs) has been shown to produce a synergistic effect on 
postoperative inﬂ  ammation (Flach 1994; Heier et al 2000).
Topical NSAIDs reduce inﬂ  ammation by inhibiting prostaglandin synthesis and 
have been shown to be clinically effective in controlling inﬂ  ammation after cataract 
surgery (Flach et al 1988; Flach et al 1998; Heier et al 1999; Simone and Whitacre 
2001; Flach 2002; Bodaghi et al 2005). Several clinical studies have shown that 
NSAIDs are as effective as steroids in the treatment of postoperative pain and inﬂ  am-
mation (Flach et al 1989; Brennan et al 1993; Simone et al 1999; Reddy et al 2000). 
The NSAIDs ketorolac 0.5% (Allergan Inc, Acular®, Irvine, CA, USA), diclofenac Clinical Ophthalmology 2007:1(4) 528
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0.1% (Novartis Ophthalmics, Voltaren Ophthalmic®, Duluth, 
GA, USA), and bromfenac 0.09% (ISTA Pharmaceuticals 
Inc, Xibrom™, Irvine, CA, USA) are all available in some 
markets for the treatment of postoperative inﬂ  ammation 
following cataract surgery.
Pre-operative initiation of NSAID therapy may reduce 
postoperative inﬂ  ammation more than when treatment is 
initiated after surgery (Roberts 1996; Solomon et al 1997; 
Flach 2002). Pre-operative regimens may initiate treatment 
anywhere from 3 days to immediately prior to surgery; 
regardless, pre-operative treatment with NSAIDs followed 
by postoperative combination therapy with NSAIDs and 
steroids has become common practice for the prevention and 
treatment of ocular inﬂ  ammation following cataract surgery 
(Flach 2002).
Nepafenac 0.1% (Alcon Laboratories Inc, Nevanac®, 
Fort Worth, TX, USA) is a new ophthalmic NSAID and is 
the only one with a prodrug structure, making it a neutral 
molecule. This property, unlike the acidic nature of the 
other topical NSAIDs, allows nepafenac to rapidly pen-
etrate the cornea, after which it is converted by intraocular 
hydrolases to its more active moiety amfenac (Ke et al 
2000). Nepafenac is unique, in that its bioconversion to 
amfenac is targeted to the iris/ciliary body and, to an even 
greater extent, the retina/choroid, suggesting nepafenac 
may have prolonged activity in the vascularized tissues 
of the eye (Ke et al 2000). In support of this hypothesis, a 
rabbit model of paracentesis-induced ocular inﬂ  ammation 
demonstrated that nepafenac exhibited a more complete 
and longer lasting inhibition of iris/ciliary body prostaglan-
din synthesis than diclofenac (Gamache et al 2000). The 
same was true in the posterior segment of the eye, where 
nepafenac demonstrated superior inhibition of retina/cho-
roid prostaglandin synthesis compared to diclofenac. Taken 
together, this preclinical evidence suggests that nepafenac 
would compare favorably to conventional NSAIDs in the 
prevention and treatment of ocular inﬂ  ammation associated 
with cataract surgery.
This study was designed based on regulatory guidance 
to compare the effectiveness of nepafenac 0.1% to both 
placebo and a well-studied NSAID (ketorolac 0.5%) for 
the prevention and treatment of pain and inﬂ  ammation fol-
lowing cataract surgery (Flach et al 1988; Flach et al 1998; 
Heier et al 1999; Simone et al 1999; Heier et al 2000). The 
primary objective of this study was to compare the effect of 
nepafenac 0.1% and placebo on anterior segment inﬂ  amma-
tion at Day 14. All other comparisons of nepafenac 0.1% to 
ketorolac 0.5% and placebo for the prevention and treatment 
of postoperative pain and inﬂ  ammation were performed at 
all time points. The dosing of the study drugs (three times 
daily) was congruent with the approved labeling of ketorolac 
0.5% in Europe and was the most effective dosing regimen 
of nepafenac 0.1% demonstrated in a prior clinical study 
(Stewart 2005).
Materials and methods
Test, active, and control articles
Nepafenac Ophthalmic Suspension, 0.1% (nepafenac 0.1%) 
and nepafenac vehicle (placebo) were supplied by Alcon 
Laboratories, Inc. Ketorolac Tromethamine Ophthalmic 
Solution, 0.5% (ketorolac 0.5%) was supplied by Allergan, 
Inc. Nepafenac 0.1%, ketorolac 0.5% and placebo were 
sterile-transferred into identical bottles by Alcon Labora-
tories, Inc.
Study design
This was a multi-center, randomized, placebo- and active-
controlled, double-masked clinical trial conducted at 15 
ophthalmology clinics in France, Hungary, Italy, Portugal, 
Spain, and the UK. The study was approved by the appro-
priate Institutional Review Boards; patients underwent 
a process of informed consent. Patients were randomly 
assigned to one of three treatment groups: nepafenac 0.1%, 
ketorolac 0.5%, or placebo. Patients instilled 1 drop 3 times 
daily beginning 1 day before surgery, continuing on the day 
of surgery, and for 21 days thereafter. Additional medica-
tion was not dispensed unless the investigator declared a 
patient to be a treatment failure, at which time the patient 
was discontinued from the study. Treatment failure was 
deﬁ  ned as a patient presenting at any postoperative visit with 
more than 15 cells, very dense ﬂ  are, or investigator-assessed 
ocular pain score of grade 4 or 5 on a 6-point ordered cat-
egorical scale from 0 (none) to 5 (severe). Patients were 
considered cured if the sum of their aqueous cells and ﬂ  are 
ratings was 0 (ie, absence of cells and ﬂ  are) at the current 
and all subsequent study visits. Clinical success was deﬁ  ned 
as an aqueous cells rating of 0 (none) or 1 (1–5 cells) and 
an aqueous ﬂ  are rating of 0 (none) at the current and all 
subsequent study visits.
Postoperative examinations were conducted on Days 1, 
3, 7, 14, 21, and 28; patients were required to have received 
a dose of their test article within 1–4 hours of each visit, 
except at Day 28 (the test article was stopped at Day 21). 
At the Day 7 visit, patients received dosing at the study site, 
after which the patients rated ocular discomfort on a 5-point 
scale from 0 (none) to 4 (severe).Clinical Ophthalmology 2007:1(4) 529
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Inclusion and exclusion criteria
Eligible patients were those who were 18 years or older, 
in need of cataract extraction by phacoemulsiﬁ  cation and 
implantation of a posterior chamber intraocular lens (IOL), 
and who met all informed consent requirements. Exclusion 
criteria included the use of topical ocular, inhaled or systemic 
steroids within 14 days prior to surgery or topical ocular, 
inhaled or systemic NSAIDs within 7 days of surgery (except 
for up to 100 mg of aspirin), any cells or ﬂ  are, investigator-
assessed ocular pain at the pre-operative baseline visit, any 
corneal abnormality that prevented reliable Goldmann appla-
nation tonometry, prior cataract surgery in the fellow eye 
within 60 days of screening visit or planned cataract surgery 
in the fellow eye prior to the Day 28 visit, planned multiple 
procedures during cataract/IOL implantation surgery (except 
for relaxing keratotomy for the correction of astigmatism), 
known or suspected hypersensitivity to NSAIDs or to any 
component of the study drugs, and a history of chronic or 
recurrent inﬂ  ammatory eye disease in the study eye.
Post-operative examinations
At the Day 1, 3, 7, 14, 21, and 28 visits, the following 
examinations were performed: best-corrected logMAR visual 
acuity, intraocular pressure measurement, investigator assess-
ment of ocular pain, and slit-lamp evaluation of the anterior 
segment (aqueous cells and ﬂ  are). Additionally, at the Day 
7 visit, patients assessed ocular discomfort following instil-
lation of the study drug. A dilated fundus examination was 
conducted at the Day 28 visit.
Safety analysis
All patients receiving study medication were included in the 
safety analysis. Safety evaluation included adverse event 
reports (solicited and voluntary) and ocular parameters 
(best-corrected logMAR visual acuity, intraocular pres-
sure measurement, slit-lamp evaluation, and dilated fundus 
examination).
Statistics
All statistical analyses were conducted on the intent-to-treat 
data set. The primary efﬁ  cacy variable was the percentage of 
patients who achieved a cure at Day 14, deﬁ  ned as aqueous 
cells score = 0 and aqueous ﬂ  are score = 0. A chi-square 
test of independence was conducted to assess the superior-
ity of nepafenac 0.1% relative to placebo at Day 14. Eye 
drop comfort evaluation at the Day 7 visit was conducted 
for nepafenac 0.1% compared to ketorolac 0.5% as well as 
placebo using two-sample t-tests.
Additional analyses were conducted for nepafenac 0.1% 
compared to placebo and ketorolac 0.5% for percentage of 
patients with clinical success (aqueous cells score = 0 or 1 
and aqueous ﬂ  are score = 0) and for investigator assessment 
of ocular pain. Chi-square tests of independence were con-
ducted to assess the superiority of nepafenac 0.1% relative 
to ketorolac 0.5% and placebo at each time point.
Results
Of 360 screened patients, 227 patients were enrolled in this 
study (77 nepafenac, 73 ketorolac, and 77 placebo). All 227 
patients received at least one dose of study medication and 
were therefore included in the safety analysis. Patients who 
received study medication, completed cataract surgery, and 
had at least one follow-up visit were included in the intent-
to-treat (ITT) population, which accounted for 225 of the 
227 patients enrolled in the study.
Patient demographics are shown in Table 1. The mean 
age of the total population was 72 years, with ages rang-
ing from 42 to 90. Forty percent of patients were male and 
over 96% were Caucasian. The groups were statistically 
equivalent with regard to age, gender, race and difﬁ  culty of 
cataract surgery.
Figure 1 illustrates the cure rates of nepafenac 0.1% 
and placebo at Day 14, the primary endpoint of this study. 
Signiﬁ  cantly more patients treated with nepafenac 0.1% 
were cured compared to those treated with placebo (76.3% 
vs 59.2%, p = 0.0241). Figure 2 shows the cure rates of all 
3 treatment groups across all postoperative visits. Although 
the nepafenac group had a higher cure rate than the placebo 
group from Day 3 onward, only the Day 14 visit reached 
statistical signiﬁ  cance (p = 0.0241). No signiﬁ  cant difference 
in cure rates between the nepafenac and ketorolac groups was 
observed at any time point.
Table 1 Patient demographics (intent-to-treat population)
 Nepafenac    Ketorolac  Placebo 
 (n  = 76) (n  = 73) (n  = 76)
  n (%)  n (%)  n (%)
Age (mean years) 71.7  72.9  71.6
Sex
  Male  34 (44.7)  28 (38.4)  28 (36.8)
  Female  42 (55.3)  45 (61.6)  48 (63.2)
Race
  Caucasian  74 (97.4)  70 (95.9)  73 (96.1)
  Black  0  2 (2.7)  1 (1.3)
 Asian  1  (1.3)  0  2  (2.6)
  Hispanic  1 (1.3)  1 (1.4)  0
Note: No statistically signiﬁ  cant differences were observed among groups.Clinical Ophthalmology 2007:1(4) 530
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As shown in Figure 3, significantly more patients 
achieved clinical success with nepafenac 0.1% than with 
placebo beginning on Day 7 and continuing through Day 28 
(p   0.05). The clinical success rate of nepafenac 0.1% was 
superior to that of ketorolac 0.5% at Day 14 (p = 0.0319). At 
other time points, the clinical successes of nepafenac 0.1% 
and ketorolac 0.5% were not statistically different.
The percentage of patients with no ocular pain was 
signiﬁ  cantly higher in the nepafenac 0.1% group compared 
to the placebo group at each time point starting with Day 
3 (Figure 4, p   0.05). Furthermore, more patients treated 
with nepafenac 0.1% were pain-free compared to those 
treated with ketorolac 0.5% at Day 3 (p = 0.0366). At other 
time points, the percent of patients with no ocular pain was 
Figure 1 Percentage of patients cured (no aqueous cells or ﬂ  are) at Day 14 with nepafenac 0.1% or placebo.
*p = 0.0241, chi-square test.
Note: The number at the bottom of each bar represents the number of evaluable patients in each arm.
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Figure 2 Cure rate of nepafenac 0.1%, ketorolac 0.5%, and placebo at each visit.
*p = 0.0241, chi-square test.
Note: The numbers at the bottom of the Day 1 bars represent the number of evaluable patients in each arm. The number of evaluable patients did not vary across time 
points.
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not statistically different between the nepafenac 0.1% and 
ketorolac 0.5% groups.
At the Day 7 visit only, patients evaluated the ocular dis-
comfort of the study medication. Mean ocular discomfort was 
signiﬁ  cantly lower for nepafenac 0.1% compared to ketorolac 
0.5% (p = 0.0158) but not to placebo (Figure 5).
All 227 patients who were enrolled in the study received at 
least one dose of study drug and were therefore included in the 
safety analysis. Two serious adverse events (hospitalizations 
due to diabetes mellitus and a branch retinal vein occlusion) 
were reported, both of which were unrelated to the use of study 
medication. Adverse events in the overall safety population 
were predominantly mild or moderate in intensity, and gener-
ally did not interrupt patient continuation in the study. The most 
frequent treatment-related adverse event with nepafenac 0.1% 
was eyelid margin crusting (2.6%); no eyelid margin crusting 
was reported with ketorolac 0.5% or placebo. For patients 
treated with ketorolac 0.5% or placebo, ocular hyperemia was 
Figure 3 Clinical success rate of nepafenac 0.1%, ketorolac 0.5%, and placebo at each visit.
*nepafenac 0.1% vs placebo, chi-square test. †nepafenac 0.1% vs ketorolac 0.5%, chi-square test.
Note: The numbers at the bottom of the Day 1 bars represent the number of evaluable patients in each arm. The number of evaluable patients did not vary across time 
points.
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Figure 4 Pain-free rate of nepafenac 0.1%, ketorolac 0.5%, and placebo at each visit.
*nepafenac 0.1% vs placebo, chi-square test. †nepafenac 0.1% vs ketorolac 0.5%, chi-square test.
Note: The numbers at the bottom of the Day 1 bars represent the number of evaluable patients in each arm. The number of evaluable patients did not vary across time 
points.
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Figure 5 Mean ocular discomfort of eye drops at Day 7.
*p = 0.0158 nepafenac 0.1% vs ketorolac 0.5%, t-test, on a 0 to 5 scale.
Note: The number at the bottom of each bar represents the number of evaluable patients in that arm. Sixteen patients had missing ocular discomfort scores, for a total of 
209 evaluable patients.
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the most frequent adverse event (2.7% and 5.2%, respectively), 
whereas the nepafenac group did not experience ocular 
hyperemia. No clinically relevant differences were observed 
between the treatment groups in the overall safety population. 
No safety concerns were identiﬁ  ed for intraocular pressure, 
visual acuity, ocular signs (corneal edema, bulbar conjunctival 
injection, and chemosis), or dilated fundus parameters based 
upon an analysis of changes from baseline.
Discussion
Nepafenac 0.1% is the newest topical NSAID available for 
the treatment of ocular pain and inﬂ  ammation associated with 
cataract surgery. It has unique properties, including rapid 
corneal permeability and targeted intraocular activation due 
to its prodrug structure.
As expected from previous studies (Stewart 2005; Lane 
et al 2007), nepafenac 0.1% met its primary objective in the 
current study by demonstrating superiority over placebo in 
the percentage of patients with clinical cures at Day 14. In 
addition, nepafenac 0.1% produced more clinical successes 
than placebo at every time point beginning with Day 7. This 
conﬁ  rms that nepafenac 0.1% is effective in the prevention 
and treatment of ocular inﬂ  ammation. Nepafenac 0.1% 
was also superior to placebo in the management of pain, as 
shown by the fact that signiﬁ  cantly more patients treated 
with nepafenac 0.1% were pain-free at every time point 
after Day 1. By Day 14, over 90% of patients treated with 
nepafenac 0.1% reported no pain, suggesting that this drug 
is highly effective in the treatment of pain related to cataract 
surgery. In fact, nepafenac has shown analgesic efﬁ  cacy in 
PRK-related ocular pain (Colin and Paquette 2006).
Most interesting, however, is the comparison between 
nepafenac 0.1% and ketorolac 0.5%. Previous studies have 
established the effectiveness of ketorolac 0.5% for the treatment 
of both pain and inﬂ  ammation following cataract surgery (Flach 
et al 1988; Flach et al 1989; Heier et al 1999; Simone et al 1999; 
Solomon et al 2001). Therefore, ketorolac 0.5% was used as 
a benchmark against which the efﬁ  cacy of nepafenac 0.1% 
was measured. The current study was not powered to detect 
the superiority of nepafenac 0.1% relative to ketorolac 0.5%. 
Despite this fact, nepafenac 0.1% reached statistical superior-
ity compared to ketorolac 0.5% in both clinical success rate 
at Day 14 and pain assessment at Day 3. This illustrates the 
robust nature of the data and indicates that nepafenac 0.1% is 
an effective and safe drug in treating ocular inﬂ  ammation.
Ocular comfort of any topical medication is important, 
as this factor may have implications for patient compliance. 
In this study, the mean ocular discomfort score of nepaf-
enac 0.1% was statistically lower than the mean score for 
ketorolac 0.5%, showing that patients judged nepafenac to 
be more comfortable upon instillation. At least two reasons 
could contribute to this difference. First, there may simply be 
molecular differences between nepafenac and ketorolac that 
result in the increased ocular comfort of nepafenac. Another 
possible explanation is that nepafenac 0.1% is formulated as 
a suspension whereas ketorolac 0.5% is a solution. Because Clinical Ophthalmology 2007:1(4) 533
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of the discomfort associated with the instillation of ketorolac 
0.5%, a less concentrated form (0.4%) has been developed to 
reduce patient complaints of stinging and burning. In clinical 
trials with ketorolac 0.5%, up to 40% of patients reported 
stinging and burning (Acular package insert 2002). However, 
in clinical trials with ketorolac 0.4%, a similar number of 
patients (20%–40%) complained of stinging and burning 
upon instillation (Acular LS package insert 2003). In the 
only head-to-head trial of these 2 agents in patients under-
going cataract surgery, ketorolac 0.4% signiﬁ  cantly reduced 
stinging and burning compared to ketorolac 0.5% at Day 1 
(20% vs 65%, p = 0.001), but not at Week 1 (50% vs 40%) 
or Month 1 (30% vs 40%; Sandoval et al 2006).
This study demonstrates that nepafenac 0.1% is superior 
to placebo for the prevention and treatment of ocular pain 
and inﬂ  ammation resulting from cataract surgery. Nepafenac 
also shows at least equal efﬁ  cacy (for both ocular pain and 
inﬂ  ammation measures) compared to ketorolac 0.5%. More-
over, nepafenac 0.1% is more comfortable upon instillation 
than ketorolac 0.5%.
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